Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

on MSN ago, source:

A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 ...

Cullinan rebrands with $280M private offering, expands beyond cancer

9d ago, source:

The Cambridge developer said on Tuesday it plans to continue development of its drug, CLN-978, in autoimmune diseases rather ...

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

9d ago, source:

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show ...

CGEM Cullinan Therapeutics, Inc.

28d ago, source: Seeking Alpha

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619 ...

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

9d ago, source: Business Insider

April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, ...

Analyzing the Price-to-Earnings Ratio of Cullinan Therapeutics Inc (CGEM)

3d ago, source: newsheater

Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -37.4. The debt to equity ...

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

9d ago, source: Stockhouse

April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing ...

CGEM Cullinan Therapeutics, Inc.

29d ago, source: Seeking Alpha

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619 ...

Cullinan Therapeutics Inc CGEM

9d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Cullinan Therapeutics Inc.

10mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cullinan Therapeutics Inc CGEM

9d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...